$95M raised by Taysha for clinical trials of four new gene therapies
FierceBiotech - 05-Aug-2020Company has gathered support from investors to quickly lead therapies to clinic then market
Join the club for FREE to access the whole archive and other member benefits.
Biotechnology company focused on advancing AAV-based gene therapies for severe monogenic diseases of the CNS
Taysha Gene Therapies is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside.
Visit website: https://tayshagtx.com/
Details last updated 12-Aug-2020
Company has gathered support from investors to quickly lead therapies to clinic then market